The Efficacy Of Betahistine Combines With Olanzapine In Cognitive Impairment Associated With Schizophrenia

Objectives To explore the effect of olanzapine combine with betahistine treatment on the cognitive function of patients with chronic schizophrenia.Methods Selected patients with chronic schizophrenia who were hospitalized in Beijing Huilongguan Hospital and met the diagnostic criteria for schizophrenia.Inclusion criteria:age 20-60 years;course of disease≥5 years;years of education≥9 years;receiving olanzapine monotherapy,stable medication≥1 month.Exclusion criteria: pregnancy and lactation;patients with severe physical and central system diseases;patients using drugs that affect cognitive function;MECT treatment within 2 weeks;betahistine contraindications: active peptic ulcer,bronchial asthma,adrenal glands Medulloma.Thirty community residents matching the gender,age,and years of education of schizophrenia were recruited as healthy control groups,and severe physical diseases,infections and immune diseases,pregnancy and lactation,mental diseases and substance dependence were excluded.Patients with chronic schizophrenia were randomly divided into groups.24 patients treated with olanzapine combined with betahistine served as the study group,and 23 patients treated with olanzapine plus placebo served as the control group;general clinical data of the patients were collected,respectively.Venous blood was collected at baseline and 4 weekends to determine fasting blood glucose,glycosylated hemoglobin,triglycerides,cholesterol,high-density lipoprotein,low-density lipoprotein,white blood cell count,C-reactive protein,adopted by psychiatrists and psychologists MCCB assesses the cognitive function of patients,the PANSS scale was used to assess the patients psychopathological symptoms,the CGI scale was used to assess the severity of the disease,and the TESS scale was used to assess the adverse reactions.The demographic data and venous blood of healthy control population were collected.Fasting blood glucose,glycosylated hemoglobin,triglycerides,cholesterol,high-density lipoprotein,low-density lipoprotein,white blood cell count,C-reactive protein and other indicators were tested.MCCB was used to check the cognitive function.Results 1.There was no statistical difference in TC,LDL-C,TG,GLU between the two groups(P>0.05);the mean values of WBC and CRP in patients with chronic schizophrenia were higher than those in healthy people,and HDL-C lower than the healthy population,the difference between the two groups was statistically significant(p<0.05).2.In the cognitive function test of patients with chronic schizophrenia,the information processing speed score,verbal memory score,visual memory score,social cognition score,working memory score,reasoning and problem solving score and total score of MCCB are significantly lower than those of healthy population,the difference was statistically significant(p<0.05),and the difference in attention and alertness score between the two groups was not statistically significant(p>0.05).3.There was no significant difference in CGI score,PANSS score between the study group and the control group at the end of the4 th week of treatment(p>0.05);The visual memory score difference was statistically significant(p<0.05).The information processing speed score,verbal memory score,social cognition score,attention alert score,reasoning and problem solving score,and MCCB total score of the two groups,The difference was not statistically significant(p>0.05);CRP levels in the study group were significantly reduced during the 4th week of treatment,and the difference was statistically significant(p<0.05).4.After 4 weeks of treatment,there were no statistically significant differences in side effects such as tremor,constipation,nausea and vomiting,electrocardiogram,and loss of appetite(p>0.05).Conclusions 1.Olanzapine combined with betahistine can improve cognitive functions such as working memory and visual memory in patients with schizophrenia.2.Betahistine has no significant effect on the positive symptoms,negative symptoms,general pathological symptoms and total scores of patients with schizophrenia.3.Betahistine reduces plasma C-reactive protein level.4.Combined with betahistine treatment,the patient has less adverse reactions and high safety.Figure 4;Table 14;Reference 149.